Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities (Q4670477): Difference between revisions
From MaRDI portal
Created claim: Wikidata QID (P12): Q73326314, #quickstatements; #temporary_batch_1711565664090 |
ReferenceBot (talk | contribs) Changed an Item |
||
Property / cites work | |||
Property / cites work: Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities / rank | |||
Normal rank | |||
Property / cites work | |||
Property / cites work: A Random Walk Rule for Phase I Clinical Trials / rank | |||
Normal rank | |||
Property / cites work | |||
Property / cites work: Continual Reassessment Method: A Likelihood Approach / rank | |||
Normal rank | |||
Property / cites work | |||
Property / cites work: Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer / rank | |||
Normal rank | |||
Property / cites work | |||
Property / cites work: Consistency of continual reassessment method under model misspecification / rank | |||
Normal rank |
Latest revision as of 09:26, 10 June 2024
scientific article; zbMATH DE number 2160436
Language | Label | Description | Also known as |
---|---|---|---|
English | Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities |
scientific article; zbMATH DE number 2160436 |
Statements
Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities (English)
0 references
22 April 2005
0 references
continual reassessment method
0 references
dose limiting
0 references
late-onset toxicities
0 references
likelihood-based design
0 references
phase I trial
0 references
time-to-event
0 references
0 references